NW Bio's Q2 Loss, Going Concern Warning, and Heavy Dilution
NWBO sits 36% above its 52-week low of $0.141.
Summary
NW Bio's Q2 10-Q shows a $12.3M loss, $595K cash, and a going concern warning. Heavy dilution from debt conversions continues.
Key Events · Earnings and Guidance · NWBO
-
Going Concern Warning Reiterated
With only $595,000 in cash as of June 30, 2026, management states there is substantial doubt about the company's ability to continue as a going concern for at least one year.
-
Heavy Dilution from Debt Conversions
During H1 2026, the company issued 96.3 million shares for conversion of debt and accrued interest, and after June 30 issued another 25.3 million shares for $4.1 million of convertible notes.
-
Net Loss of $12.3 Million
For the six months ended June 30, 2026, net loss was $12.3 million, improved from $34.7 million a year earlier, but still significant.
-
Yorkville Financing Follows
Subsequent to quarter end, the company entered a $4.9 million convertible note and a $50 million standby equity facility with Yorkville, adding further potential dilution.
Analysis · NWBO · Life Sciences
A net loss of $12.3 million for the first half of 2026 and a cash balance of just $595,000 underscore the precarious position of Northwest Biotherapeutics. Management reiterates substantial doubt about the company's ability to continue as a going concern. The 10-Q also reveals aggressive debt-to-equity conversions: 96.3 million shares issued for debt conversion in the first half, plus 25.3 million more shares issued after June 30. Combined with the recent Yorkville financing, this heavy dilution highlights the company's fragile financial state.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NWBO was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $325.2M. The 52-week trading range was $0.14 to $0.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.